Which has the lower trailing P/E, BSX or TEVA?

BSX has the lower trailing P/E: BSX trades at 18.31 and TEVA at 64.53. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BSX or TEVA?

Over the past five years, BSX grew revenue faster — BSX at a 13.40% CAGR versus TEVA at 1.19%.

Is BSX or TEVA more profitable?

BSX runs the higher net margin — BSX at 17.47% versus TEVA at 4.08%.

How have BSX and TEVA total returns compared?

Over the past 10 years, BSX delivered 6.22% and TEVA delivered -2.58% annualized total return. Past performance doesn't predict future results.

Boston Scientific Corporation (BSX) vs Teva Pharmaceutical Industries Limited (TEVA)

A side-by-side comparison of Boston Scientific Corporation and Teva Pharmaceutical Industries Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.

BSX

Boston Scientific Corporation

$66.96B

$45.05HealthcareDelayed quote: Sep 14, 2026, 4:00 PM EDT

TEVA

Teva Pharmaceutical Industries Limited

$45.09B

$38.72HealthcareDelayed quote: Sep 14, 2026, 4:00 PM EDT

Total return — BSX vs TEVA

growth of $100 · dividends reinvested · last 10y

BSX +82.8% (+6.2%/yr)TEVA -23.7% (-2.7%/yr)BSX compounded faster over this window

BSX TEVA

BSX vs TEVA: by the numbers

•BSX is the larger company ($66.96B vs $45.09B market cap).
•BSX trades at the lower trailing earnings multiple (18.31 vs 64.53 P/E), one valuation lens rather than an overall verdict.
•BSX converts more revenue to profit (17.47% vs 4.08% net margin).
•BSX grew revenue faster over the past five years (13.40% vs 1.19% CAGR).

Metrics side by side

Valuation

Metric	BSX	TEVA
P/E ratio	18.31	64.53
Forward P/E	13.70	19.48
P/S ratio	3.19	2.60
P/B ratio	2.69	5.81
EV / EBITDA	13.64	19.62
FCF yield	5.41%	2.99%

Profitability

Metric	BSX	TEVA
Gross margin	71.16%	52.47%
Operating margin	21.46%	11.45%
Net margin	17.47%	4.08%
ROE	14.71%	9.10%
ROIC	10.57%	6.79%

Growth (annualized)

Metric	BSX	TEVA
Revenue CAGR (5Y)	13.40%	1.19%
FCF CAGR (5Y)	15.64%	14.58%
Total return CAGR (5Y)	-0.67%	32.17%

Frequently asked

Which has the lower trailing P/E, BSX or TEVA?: BSX has the lower trailing P/E: BSX trades at 18.31 and TEVA at 64.53. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BSX or TEVA?: Over the past five years, BSX grew revenue faster — BSX at a 13.40% CAGR versus TEVA at 1.19%.
Is BSX or TEVA more profitable?: BSX runs the higher net margin — BSX at 17.47% versus TEVA at 4.08%.
How have BSX and TEVA total returns compared?: Over the past 10 years, BSX delivered 6.22% and TEVA delivered -2.58% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BSX analysis Full TEVA analysis Interactive comparison tool

Dig into the metrics

Boston Scientific P/E ratio Teva Pharmaceutical Industries P/E ratio Boston Scientific ROE Teva Pharmaceutical Industries ROE Boston Scientific operating margin Teva Pharmaceutical Industries operating margin Boston Scientific revenue growth Teva Pharmaceutical Industries revenue growth Boston Scientific free cash flow Teva Pharmaceutical Industries free cash flow

Boston Scientific & Teva Pharmaceutical Industries appear in these rankings

Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.